To further reveal the mechanism of how inosine impacts tumour immunogenicity, we used adenosine receptors antagonist CGS15943, which inhibits ARs downstream pathway, and inosine transport ENT1/ENT2 inhibitor Dilazep dihydrochloride, which blocks extracellular inosine into cells, to pretreat 4T1 cells and then measured the direct downstream gene signature of UBA6. This evidence concerns the gene SLC29A2 and neoplasm.